Abstract
This report:
- Covers updated aspects in the oncology industry
- Reviews markets for each of the categories of reagents used to treat
cancer and different therapies, including chemotherapy, immunotherapy, target
therapy, and sex hormones
- Analyzes spending in the reagents and therapies categories worldwide
- Studies new and different types of regulations enforced by the authorities
in the oncology field, new drugs, and recalls in the market
- Studies the market share of the different drug manufacturers and suppliers
with an emphasis on the market leaders, as well as demand and use
- Emphasizes new technologies and their uses
- Examines new patents and their significance with a statistical description
- Details present and future (2013) trends in spending in the cancer therapy
Introduction
STUDY OBJECTIVES
BCC' s goal in conducting this study is to provide an overview of the current
and potential aspects of the global market for cancer therapies. The report
determines the market size, market leaders, and factors affecting the market
for cancer therapies with the inclusion of the market by disease sector.
The overview of types of diseases and different therapies in cancer is also
examined along with sale figures over the 5-year period from 2008 to 2013.
Companies manufacturing/selling the drugs to treat cancer are profiled, and
the factors affecting markets for these products and how those markets are
likely to change are analyzed. Revenues have been broken down by the type of
therapies and by different regions.
Our key objective is to present a comprehensive analysis of the current and
future market and to analyze the future direction of cancer therapies with an
emphasis on newer products.
REASONS FOR DOING THIS STUDY
Due to continuous technology advances in research and development in the field
of oncology and the requirement for newer and more effective pharmaceutical
drugs/therapies, companies are investing in the development of these new
products to lessen the side effects and target the disease. A fundamental
change in cancer therapies is underway with a shift from the use of
chemotherapy drugs to targeted therapy or the use of chemotherapy drugs along
with targeted therapies. Targeted therapies are being developed for targeting
cancer cells more specifically. Targeted therapies are more efficacious and
less toxic than chemotherapy due to their more selective nature.
This study looks at almost all types of therapies/products used in oncology.
The study conducts the prevalence of cancer globally. The research and
development of new products and major changes in market behavior justify
focusing on this segment. Finally, this study discusses the usage of these
drug therapies by disease sector to determine the usage in each sector.
CONTRIBUTIONS of THE STUDY and for whom
The study contributes to the areas of market growth and decline in cancer
therapies from the point of view of manufacturers and users. This study will
be of interest largely to the pharmaceutical and biopharmaceutical industries,
clinics, and hospitals.
SCOPE of the study
The scope of this study encompasses the markets for cancer therapies. BCC
analyzes each market and its market leaders; different types of therapies; the
prevalence of cancer; the regulatory environment; the different disease
sectors for cancer; and market projections and market share. Technological
issues include the latest trends and new developments
METHODOLOGY
Both primary and secondary sources were used for this research. A
comprehensive literature search was conducted. The literature included
technical newsletters and journals as well as many other sources. The data
were collected through interviews and correspondence with various
pharmaceutical/biotechnical experts. Projections were based on estimates such
as the current number of end users, potential end users, likely unit prices,
rates of consumption, and market trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. Included were
manufacturers and end users of cancer drugs. We gathered the data; spoke with
officials of this industry; and reviewed newsletters, company literature,
product literature, a host of technical articles, journals, indexes, and
abstracts. Exhaustive investigations of databases by key terminology were
done. In addition, we compiled data from current financial and trade
information and government sources.
| 
View Cart
